Rx Cost-Effectiveness Data Requirement Would Raise Prices – AstraZeneca

18 Nov 2002

• By The Pink Sheet

Requiring pharmaceutical companies to collect cost-effectiveness data would lead to higher Rx pricing, AstraZeneca CEO Tom McKillop said during the company's annual business review Nov. 7

Rx Cost-Effectiveness Data Requirement Would Raise Prices – AstraZeneca

More from Archive

More from Pink Sheet